Article ; Online: Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.
2020 Volume 81, Issue 2, Page(s) e39–e45
Abstract: ... 2 RNA.: Results: Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies ... Objectives: SARS-CoV-2 antibody assays are needed for serological surveys and as a complement ... for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV ...
| Abstract | Objectives: SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. Methods: In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA. Results: Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon). Conclusions: The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved. |
|---|---|
| MeSH term(s) | Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; Betacoronavirus/immunology ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Coronavirus Infections/diagnosis ; Coronavirus Infections/immunology ; Enzyme-Linked Immunosorbent Assay ; Female ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/immunology ; Point-of-Care Systems ; Reagent Kits, Diagnostic ; SARS-CoV-2 ; Sensitivity and Specificity ; Seroconversion ; Serologic Tests ; Young Adult |
| Chemical Substances | Antibodies, Viral ; Reagent Kits, Diagnostic |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-06-03 |
| Publishing country | England |
| Document type | Evaluation Study ; Journal Article |
| ZDB-ID | 424417-5 |
| ISSN | 1532-2742 ; 0163-4453 |
| ISSN (online) | 1532-2742 |
| ISSN | 0163-4453 |
| DOI | 10.1016/j.jinf.2020.05.077 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1501: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MG 48: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.